Ocular adverse drug reactions

Bibliography

• BRICK DC: Medication errors result in costly claims for ophthalmologists. Surv. Ophthalmol. (1995) 40(3):232–236.
   PubMed Web of Science ®Google Scholar
• BETTMAN JW: Seven hundred medicolegal cases in ophthalmology. Ophthalmology (1990) 97(10):1379–1384.
   PubMed Web of Science ®Google Scholar
• BETTMAN JW: A retrospective look at twenty-two medicolegal claims. How they might have been avoided. Surv. Ophthalmol. (1983) 28(1):55–60.
   PubMedGoogle Scholar
• BETTMAN JW: Medicolegal claims in intraocular lens implant cases. Am. J. Ophthalmol. (1981) 91(5):620–621.
   PubMed Web of Science ®Google Scholar
• EDWARDS R, BIRIELL C: Harmonisation in pharmacovigilance. Drug Saf (1994) 10(2):93–102.
   PubMedGoogle Scholar
• •First paper to categorise spontaneous reports on specific criteria making rechallenge data a compelling piece of evidence.
   Google Scholar
• FRAUNFELDER FT, FRAUNFELDER FW: Drug-induced ocular side effects (5th edn). Butterworth-Heinemann, Woburn, MA (2001) :824.
   Google Scholar
• FRAUNFELDER FT, MEYER SM: Amiodarone keratopathy. Trans. Ophthalmol. Soc. NZ (1984) 36:33–34.
   PubMedGoogle Scholar
• MANTYJARVI M, TUPPURAINEN K, IKAHEIMO K: Ocular side effects of amiodarone. Surv. Ophthalmol. (1998) 42:360–366.
   PubMed Web of Science ®Google Scholar
• ARNOLD AC: Ischemic optic neuropathies. Ophthalmol. Clin. North Am. (2001) 14(1):83–98.
   PubMedGoogle Scholar
• HAYREH SS: Anterior ischemic optic neuropathy: trouble waiting to happen. Ophthalmology (2000) 107(3):407–410.
   PubMed Web of Science ®Google Scholar
• KNOX DL, KERRISON JB, GREEN WR: Histopathologic studies of ischemic optic neuropathy. Trans. Am. Ophthalmol. Soc. (2000) 98:203-220. Discussion 221–222.
   Google Scholar
• LESSELL S: Nonarteritic anterior ischemic optic neuropathy: enigma variations. Arch. Ophthalmol. (1999) 117(3):386–388.
   PubMed Web of Science ®Google Scholar
• NEWMAN NJ, SCHERER R, LANGENBERG P et al.: The fellow eye in NAION: report from the ischemic optic neuropathy decompression trial follow-up study. Am. J. Ophthalmol. (2002) 134(3):317–328.
   PubMed Web of Science ®Google Scholar
• FEINER LA, YOUNGE BR, KAZMIER FJ, STRICKER BH, FRAUNFELDER FT: Optic neuropathy and amiodarone therapy. Mayo Clin. Proc. (1987) 62(8):702–717.
   PubMed Web of Science ®Google Scholar
• MACALUSO DC, SHULTS WT, FRAUNFELDER FT: Features of amiodarone-induced optic neuropathy. Am. J. Ophthalmol. (1999) 127(5):610–612.
   PubMed Web of Science ®Google Scholar
• •First paper to report on amiodarone optic neuropathy.
   Google Scholar
• FRAUNFELDER FW, FRAUNFELDER FT: Oculogyric crisis in patients taking cetirizine. Arch. Ophthalmol. (2003). Submitted.
   Google Scholar
• ONUAGULUCHI G: Crises in post-encephalitic parkinsonism. Brain (1961) 84:395.
   PubMed Web of Science ®Google Scholar
• MARMOR MF, CARR RE, EASTERBROOK M: Recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology (2002) 109:1377–1382.
   PubMed Web of Science ®Google Scholar
• EASTERBROOK M: Detection and prevention of maculopathy associated with antimalarial agents. Int. Ophthalmol. Clin. (1999) 39:49–57.
   PubMedGoogle Scholar
• •The American Academy of Ophthalmology sponsored this report which provides clinicians with much needed guidance in the management of patients on hydroxychloroquine.
   Google Scholar
• EASTERBROOK M: Is corneal depositionof antimalarial any indication of retinal toxicity? Can. J. Ophthalmol. (1990) 25:249–251.
   Google Scholar
• DRUKER BJ, SAWYER CL, KANTARJIAN HM: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with Philadelphia chromosome. N Engl. J. Med. (2001) 344:1038–1042.
   PubMed Web of Science ®Google Scholar
• DRUKER BJ, TALPAZ M, RESTA DJ: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl. J. Med. (2001) 344:1031–1037.
   PubMed Web of Science ®Google Scholar
• HEINRICH MC, GRIFFITH DJ, DRUKER BJ: Inhibition of c-kit receptor tyrosine kinase activity by 5TI571: targeting BCE-ABL as therapy for CML. Oncologist (2000) 96:925–932.
   Google Scholar
• MAURO MJ, DRUKER BJ: 5TI571: targeting BCE-ABL as therapy for CML. Oncologist (2001) 6:233–238.
   PubMed Web of Science ®Google Scholar
• VAN OOSTEROM A, JUDSON I, VERWEJ J: Safety and efficacy of imatinib (5TI571) in metastatic gastrointestinal stromal tumors: a Phase I study. Lancet (2001) 358:1421–1423.
   PubMed Web of Science ®Google Scholar
• DEMETRI G, VON MEHRAN M, BLANKE CD: Efficacy and safety of imitanib mesylate in advanced gastrointestinal stromal tumors. N Engl. J. Med. (2002) 347:472–480.
   PubMed Web of Science ®Google Scholar
• HASSELBALCH HC: 5TI571 (Gleevec), a new drug for the treatment of chronic myeloid leukemia. Ugeskr. Laeger (2002) 164:2914–2917.
   PubMedGoogle Scholar
• ESMAELI B, PRIETO VG, BUTLER CE et al.: Severe periorbital edema secondary to 5TI571 (Gleevec). Cancer (2002) 95(4):881–887.
   PubMed Web of Science ®Google Scholar
• FRAUNFELDER FW et al.: Ocular side effects associated with imatinib mesylate (Gleevec). J. Ocul. Pharmacol. Ther. (2003). Submitted.
   Google Scholar
• MATHERS WD, SHIELDS WJ, SACHDEV MS, PETROLL WM, JESTER JV: Meibomian gland morphology and tear osmolarity: changes with accutane therapy. Cornea (1991) 10:286–290.
   PubMed Web of Science ®Google Scholar
• FRAUNFELDER FW, FRAUNFELDER FT: Isotretinoin and intracranial hypertension. Ophthalmology (2003). Submitted.
   Google Scholar
• FRAUNFELDER FT, LABRAICO JM, MEYER SM: Adverse ocular reactions possibly associated with isotretinoin. Am. J. Ophthalmol. (1985) 100(4):534–537.
   PubMed Web of Science ®Google Scholar
• MACAROL V, FRAUNFELDER FT: Pamidronate disodium and possible ocular adverse drug reactions. Am. J. Ophthalmol. (1994) 118(2):220–224.
   PubMed Web of Science ®Google Scholar
• FRAUNFELDER FW, FRAUNFELDER FT, JENSVOLD B: Scleritis and other ocular side effects associated with pamidronate disodium. Am. J. Ophthalmol. (2003) 135(2):219–222.
   PubMed Web of Science ®Google Scholar
• FRAUNFELDER FW, FRAUNFELDER FT: Bisphosphonates and ocular side effects. N Engl. J. Med. (2003) 348(12):1187–1188.
   PubMed Web of Science ®Google Scholar
• FRAUNFELDER FT, MEYER SM: Systemic reactions to ophthalmic drug preparations. Med Toxicol. Adverse Drug Exp. (1987) 2(4):287–293.
   PubMedGoogle Scholar
• •First drug ever proven to cause scleritis.
   Google Scholar
• FRAUNFELDER FT, MEYER SM: Possible cardiovascular effects secondary to topical ophthalmic 2.5% phenylephrine. Am. J. Ophthalmol. (1985) 99(3):362–363.
   Google Scholar
• FRAUNFELDER FW, RICH LF: Possible adverse effects of drugs used in 419 Expert Op/n. Drug Saf. (2003) 2(4) refractive surgery. J. Cataract Refract. Surg. (2003) 29W:170475.
   Google Scholar
• FRAUNFELDER FW, FRAUNFELDER FT, JENSVOLD B: Adverse systemic effects from pledgets of topical ocular phenylephrine 10%. Am. J. Ophthalmol. (2002) 134(4):624–625.
   PubMed Web of Science ®Google Scholar
• LATIES AM, FRAUNFELDER FT: Ocular safety of Viagra, (sildenafil citrate). Trans. Am. Ophthalmol. Soc. (1999) 97:115-125. Discussion 125–128.
   Google Scholar
• SANKAR PS, PASQUALE LR, GROSSKREUTZ CL: Uveal effusion and secondary angle-closure glaucoma associated with topiramate use. Arch. Ophthalmol. (2001) 119(8):1210–1211.
   PubMed Web of Science ®Google Scholar
• THAMBI L, KAPCALA LP, CHAMBERS Wet al.: Topiramate-associated secondary angle-closure glaucoma: a case series. Arch. Ophthalmol. (2002) 120(8):1108.
   Google Scholar
• FRAUNFELDER FW, FRAUNFELDER FT: Topiramate-associated acute, bilateral, secondary angle-closure glaucoma. Ophthalmology (2003). Submitted.
   Google Scholar